Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis.


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 23 11 2021
accepted: 08 12 2021
pubmed: 14 12 2021
medline: 23 2 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disorder classified among the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and characterized by a triad of upper and lower respiratory tract disease, systemic vasculitis involving small-to-medium vessels and renal manifestations. Mass lesions, also described as inflammatory lesions, pseudotumor or tumour-like masses, are uncommon manifestations of GPA and are often called granuloma since histology examination shows granulomatous inflammation and rarely vasculitis. Masses could represent a localized manifestation of GPA or develop as part of a systemic disease. Unusual clinical presentation together with nonspecific radiological and histological features may delay the correct diagnosis leading to disease progression and organ damage. Diagnosis of GPA in such cases may be challenging and malignancy or infections must be considered as alternative diagnostic options. Here we reviewed all the different sites where mass lesions were reported in GPA, focusing on atypical localization, and summarized current therapeutic options and their different outcomes. We retrieved and discussed the cases reported since 2010, bearing in mind the advances in the therapeutic management of AAV patients in the last decade, namely biological therapy such as rituximab. Despite treatment regimens with glucocorticoids and immunosuppressive agents, mass lesions have a refractory course in a high proportion of patients. Invasive surgical procedures may be considered only when drug therapy fails.

Identifiants

pubmed: 34902605
pii: S1568-9972(21)00300-1
doi: 10.1016/j.autrev.2021.103018
pii:
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Immunosuppressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103018

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Roberto Padoan (R)

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.

Debora Campaniello (D)

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.

Mariele Gatto (M)

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.

Franco Schiavon (F)

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.

Andrea Doria (A)

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy. Electronic address: adoria@unipd.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH